Tarptautinis bioterapijos institutas, UAB - financials and debts
Company age: 7 y. 10 mo.
Tarptautinis bioterapijos institutas - Company finances
|
EUR
|
2018
From: 2018-11-09
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | - | - | - | - | - | 113,081 | 119,297 |
| Profit before tax | - | - | - | - | - | -3,930 | 12,226 | 8,157 |
| Net profit | 0 | 0 | 0 | 0 | 0 | -3,930 | 10,974 | 7,234 |
| Equity | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | -1,430 | 9,544 | 16,778 |
| Liabilities | 0 | 0 | 0 | 0 | 0 | 1,500 | 45,981 | 47,568 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 70 | 59,944 | 66,807 |
| Total assets | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 70 | 59,944 | 66,807 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 624 | 18,149 | 29,936 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | - | - | - | - | +5.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5614.3% | 18.3% | 10.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | 115.0% | 43.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | - | - | 9.7% | 6.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | 10.8% | 6.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | 4.8 | 2.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | 37,694 | 39,766 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Tarptautinis bioterapijos institutas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-26 | 2026-09-02 | 105.33 |
| 2026-08-23 | 2026-08-23 | 105.33 |
| 2026-08-19 | 2026-08-19 | 105.33 |
| 2025-06-17 | 2025-07-06 | 0.03 |
| 2025-05-16 | 2025-06-02 | 0.03 |
| 2025-05-04 | 2025-05-04 | 0.03 |
| 2025-04-30 | 2025-04-30 | 0.01 |
| 2025-04-24 | 2025-04-29 | 0.03 |
| 2025-04-16 | 2025-04-23 | 0.01 |
| 2025-03-19 | 2025-04-06 | 0.01 |
| 2025-02-20 | 2025-03-05 | 0.01 |
| 2025-02-18 | 2025-02-19 | 72.76 |
| 2025-02-10 | 2025-02-10 | 0.01 |
| 2025-01-16 | 2025-02-04 | 0.01 |
| 2025-01-02 | 2025-01-06 | 0.01 |
| 2024-12-22 | 2024-12-31 | 0.01 |
| 2024-12-17 | 2024-12-20 | 0.01 |
| 2024-11-18 | 2024-12-05 | 0.01 |
| 2024-10-16 | 2024-11-07 | 0.01 |
| 2024-09-17 | 2024-10-08 | 0.01 |
| 2024-08-19 | 2024-09-09 | 0.01 |
| 2024-07-24 | 2024-08-08 | 0.01 |
| 2024-04-16 | 2024-04-17 | 40.58 |
Tarptautinis bioterapijos institutas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-01 | 2025-01-01 | 35.87 |
| 2024-12-31 | 2024-12-31 | 35.78 |
| 2024-12-29 | 2024-12-30 | 35.79 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Tarptautinis bioterapijos institutas, UAB (Private Limited Liability Company), code 304947957, operates in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of €119.3K, up 5.5% year on year, and net profit of €7.2K, with a 6.1% net margin. Profitability eased from 2024, when revenue was €113.1K and net profit €11.0K, but the company remained profitable after a loss of €3.9K in 2023. The three-year pattern shows a move from very small-scale activity and negative equity in 2023 to positive earnings in 2024 and 2025. At the end of 2025, total assets were €66.8K, equity €16.8K, and liabilities €47.6K, giving an equity ratio of 25.1% and debt-to-equity of 2.84. Asset turnover was 1.79x. Revenue per employee was €39.8K and profit per employee €2.4K, indicating limited but positive operating productivity.